Drug Search Results
More Filters [+]

HLX-1502

Alternative Names: HLX-1502, HLX 1502, HLX1502
Latest Update: 2024-08-07
Latest Update Note: Clinical Trial Update

Product Description

HLX-1502 was discovered by Healx’s proprietary AI drug discovery platform, and has a first in class mechanism for the treatment of Neurofibromatosis Type 1. Healx aims to develop HLX-1502 for both plexiform and cutaneous subtypes of NF1, thus enabling access to treatment for a wide range of NF1 patients. Healx plans to submit an Investigational New Drug (IND) application to take its wholly-owned HLX-1502 program into clinical trials in 2024. (Sourced from: https://healx.ai/healx-receives-us-orphan-drug-designation-for-its-ai-discovered-treatment-of-neurofibromatosis-type-1/)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Healx
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HLX-1502

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title